Table 2. Lipids, lipoproteins and metabolic markers according to LIPC genotypes and case-control design.

		Cases			Controls
							p value forcase-controleffect	p value forLIPCeffect
	CC	CT	TT	CC	CT	TT
Numbers of subjects	322	196	39	356	192	12
TC (g/L)	1.99 (0.43)	2.05 (0.38)	2.08 (0.52)	2.22 (0.35)	2.29 (0.41)	2.35 (0.51)	0.001	0.03
HDLc (g/L)	0.43 (0.12)	0.43 (0.14)	0.44 (0.10)	0.55 (0.12)	0.56 (0.14)	0.62 (0.12)	0.001	0.31
LDLc (g/L)	1.25 (0.37)	1.27 (0.34)	1.31 (0.48)	1.45 (0.32)	1.47 (0.35)	1.49 (0.42)	0.001	0.40
TG (g/L)*	1.62 (0.96)	1.77 (0.91)	1.73 (0.91)	1.13 (0.61)	1.30 (1.02)	1.33 (0.74)	0.001	0.02
Apo A-1 (g/L)	1.22 (0.21)	1.23 (0.25)	1.27 (0.18)	1.51 (0.23)	1.52 (0.25)	1.68 (0.21)	0.001	0.07
Apo B (g/L)	1.04 (0.23)	1.07 (0.22)	1.10 (0.32)	1.09 (0.21)	1.13 (0.22)	1.13 (0.28)	0.001	0.04
Apo E (g/L)*	99.6 (59.3)	108.5 (61.4)	100.7 (71.9)	72.3 (42.3)	79.7 (55.2)	67.1 (43.8)	0.001	0.12
Apo C3 (g/L)*	32.3 (12.5)	34.3 (12.8)	39.6 (23.5)	30.2 (11.9)	31.5 (14.7)	35.8 (16.8)	0.001	0.009
Glycaemia (g/L)*	1.11 (0.41)	1.06 (0.35)	1.10 (0.45)	0.97 (0.17)	0.99 (0.20)	1.00 (0.19)	0.001	0.86
Insulin (IU/L)*	16.1 (21.3)	14.9 (23.6)	23.1 (38.5)	9.5 (6.8)	10.5 (7.8)	10.8 (6.9)	0.001	0.37
HOMA-IR*	4.9 (11.8)	4.1 (6.5)	6.5 (10.9)	2.4 (2.1)	2.7 (2.7)	2.8 (2.3)	0.001	0.45
Adiponectin (mg/L)	5.8 (4.2)	6.0 (5.1)	6.0 (4.6)	7.2 (4.9)	6.6 (3.9)	4.8 (3.3)	0.001	0.62
Metabolic syndrome (NCEP-ATPIII)	52.8%	46.9%	48.7%	16.3%	17.7%	16.6%	0.001	0.72

^*Analyses were performed on log transformed data.